Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: April 23, 2026
Principal Executive Office: Marseille, France
Context: This filing serves as a cover document for a press release (Exhibit 99.1) dated April 23, 2026. The text provided contains only the cover page and signature block; the content of the press release is not included in the source text.
Key Financial Metrics
The provided filing text does not contain financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not available in this document.
Material Changes
No material changes or comparative financial data are present in the provided text.
Guidance, Outlook, and Risks
The filing references a press release but does not include its text. Therefore, no guidance, management commentary, risks, contingencies, or unusual items can be summarized from the source provided.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 (Press Release dated April 23, 2026) to understand the specific event triggering this filing.
- Confirm if the press release contains updated clinical trial data, regulatory milestones, or financial updates not present in the cover page.
- Review the company's most recent Form 20-F for the latest audited financial statements, as this 6-K does not provide them.